TRANQUILITY trial results strengthen case for pacibekitug as a potential quarterly IL-6 inhibitor for cardiovascular inflammation in chronic …
TRANQUILITY trial results strengthen case for pacibekitug as a potential quarterly IL-6 inhibitor for cardiovascular inflammation in chronic …
Dual clinical studies reveal statistically meaningful benefits for patients with MSA, highlighting a leap forward for disease-modifying treatment …
Phase III ASCENT-04/KEYNOTE-D19 trial reveals meaningful PFS improvement with a novel antibody-drug conjugate/immunotherapy combo
Enhertu combo shows promise in metastatic breast cancer while Arvinas reveals hopeful data on a novel lymphoma proteolysis …
A key regulation is poised to reshape clinical research in Britain—reducing red tape, elevating patient voices and strengthening …
New data reveals that smaller biopharma players are gaining ground in innovation, contributing a growing share of first-in-class …
A landmark study from MHRA and University of Liverpool reveals the UK’s leadership in drug development and outlines …
An investigational RNA-based therapy shows significant reduction in disease-causing protein levels—potentially a meaningful step forward in treating Huntington’s …
Topical laquinimod reaches posterior eye tissues with dose-related distribution and good tolerability in patients preparing for vitrectomy
The biotech sector saw compelling developments from funding milestones to shifts in trial regulations and rising promise in …
Already a subscriber? Log in